ASCO 2016 – Lung Cancer

Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Page 3 of 3

1
2
3